Free delivery over $3201–3 day express deliveryDispatched Australia-wideIndependent lab reports published
Free bac water with any 2 vials · no code · ends Thu 26 NovBlack Fridayopens Fri 27 Nov ·  
Shop now

BPC-157 + TB-500 – 20mg

$130.00

BPC-157 + TB-500 20mg is an experimental two-component peptide blend associated with preclinical tissue biology, cellular migration, angiogenesis-related signalling and molecular research.

Available from Peps Aussie Australia for controlled laboratory research and analytical applications.

  • Product: BPC-157 + TB-500
  • Total Labelled Size: 20mg
  • Material Type: Two-component peptide research blend
  • Component 1: BPC-157 — synthetic pentadecapeptide
  • Component 2: TB-500 — thymosin beta-4-associated material
  • Research Areas: Cellular migration, tissue-associated responses and angiogenesis-related pathways
  • Component Ratio: Not specified; requires lot-specific verification
  • TB-500 Identity: Exact molecular sequence requires verification
  • Quality Documentation: Available Certificates of Analysis (COA)
  • Shipping: Australian dispatch, subject to stock availability
  • Intended Use: Scientific and laboratory research only

The 20mg label refers to the combined quantity and does not establish a 10mg + 10mg split.

For laboratory research use only. Not intended for human or animal consumption, administration, injury recovery, tissue repair or therapeutic use.

Free Delivery on all orders above $320

Out of stock

Description

BPC-157 + TB-500 20mg – Tissue Biology and Cellular Migration Research Blend Australia

BPC-157 + TB-500 20mg is an experimental two-component peptide research blend listed by Peps Aussie Australia as reference material for scientific investigation, laboratory analysis and controlled experimental research.

The formulation is described as combining BPC-157, a synthetic peptide investigated in preclinical tissue-response models, with TB-500, a commercial designation associated with thymosin beta-4-derived peptide material.

These components have been discussed in scientific research involving cellular migration, tissue-associated signalling, angiogenesis-related pathways and experimental responses to cellular injury.

BPC-157 has been investigated primarily in animal and laboratory models examining gastrointestinal biology, connective tissue responses and selected molecular signalling pathways.

Thymosin beta-4 and related peptide fragments have been investigated in relation to actin-associated cellular processes, cell migration and tissue biology.

However, research involving thymosin beta-4 does not automatically establish the molecular identity or biological activity of commercially labelled TB-500.

The exact sequence of TB-500 must be verified against the applicable product documentation.

Similarly, the biological characteristics of BPC-157 and TB-500 individually do not establish that combining them produces additive or synergistic effects.

Published evidence directly evaluating the specific BPC-157 + TB-500 combination is limited.

Peps Aussie lists the blend in a nominal total size of 20mg.

The combined strength does not establish the quantity or proportion of either individual component.

Researchers should verify the identity, content and ratio of both components against the applicable product label and lot-specific analytical documentation.

Important: BPC-157 + TB-500 is intended strictly for laboratory research and analytical purposes. It is not supplied for human or animal consumption, injection, administration, injury treatment, tissue repair, sports recovery, bodybuilding or therapeutic use.

What Is BPC-157 + TB-500?

BPC-157 + TB-500 is a two-component experimental research blend combining peptides associated with different areas of preclinical tissue biology.

The components are chemically distinct and should be evaluated separately before interpreting any combined experimental findings.

BPC-157

BPC-157 is commonly described as a synthetic pentadecapeptide containing 15 amino acid residues.

It is associated with a peptide sequence derived from research involving a gastric protein fraction.

A commonly reported BPC-157 amino acid sequence is:

Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val

One-letter sequence:

GEPPPGKPADDAGLV

BPC-157 has been investigated in preclinical studies involving tissue-associated signalling, gastrointestinal models and experimental cellular responses.

However, the mechanisms proposed in these studies remain incompletely established, and findings from animal models do not demonstrate clinical efficacy in humans.

TB-500

TB-500 is a commercial designation commonly associated with thymosin beta-4-derived peptide material.

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide involved in actin-associated cellular biology.

However, the name TB-500 does not consistently identify one universally standardised peptide sequence.

Some commercial materials are described as full-length thymosin beta-4, while others may be associated with shorter fragments or modified sequences.

Consequently, published findings involving full-length thymosin beta-4 should not automatically be attributed to every product labelled TB-500.

The exact molecular identity of the TB-500 component must be confirmed through suitable analytical documentation.

Why Are BPC-157 and TB-500 Discussed Together?

The two peptides are frequently discussed in relation to experimental tissue biology.

Potential research questions include:

  • Cellular migration.
  • Angiogenesis-associated signalling.
  • Extracellular matrix biology.
  • Tissue-associated molecular responses.
  • Experimental injury models.
  • Peptide interactions.
  • Comparative cellular assays.
  • Multi-component analytical characterisation.

These are areas of scientific investigation, not evidence that the blend repairs tissue or accelerates recovery.

BPC-157 + TB-500 Peptide Research and Scientific Applications

Published research involving BPC-157, thymosin beta-4 and related peptides spans experimental tissue biology, cellular migration, angiogenesis and molecular signalling.

The following sections describe relevant scientific research topics rather than proven therapeutic effects of the Peps Aussie blend.

1. Experimental Tissue Response Research

One of the primary areas associated with BPC-157 and thymosin beta-4 research involves tissue-associated responses in experimental models.

Preclinical investigations have examined how cells and tissues respond to different forms of stress or injury.

Relevant research topics include:

  • Experimental tissue models.
  • Cellular stress responses.
  • Tissue-associated signalling.
  • Molecular response pathways.
  • Comparative peptide experiments.
  • Histological observations.
  • Experimental injury models.

These investigations contribute to understanding biological processes associated with tissue responses.

However, observations in laboratory or animal models do not establish that the BPC-157 + TB-500 blend accelerates injury recovery in humans.

2. Cellular Migration Research

Cell migration is a fundamental biological process involved in development, tissue maintenance and responses to environmental conditions.

Thymosin beta-4 has been investigated in relation to actin-associated cellular processes and cell movement.

BPC-157 has also been discussed in selected preclinical models involving cellular responses.

Relevant research topics include:

  • Cellular migration.
  • Cytoskeletal regulation.
  • Actin-associated processes.
  • Cell movement assays.
  • Experimental cellular models.
  • Molecular signalling.
  • Comparative peptide responses.

These investigations contribute to understanding cellular movement and regulation.

However, findings involving full-length thymosin beta-4 should not automatically be attributed to commercially labelled TB-500 without sequence verification.

3. Angiogenesis-Associated Research

Angiogenesis is the biological process through which new blood vessels develop from existing vascular structures.

This process is relevant to development, tissue maintenance and several disease-associated pathways.

BPC-157 and thymosin beta-4 have been investigated in selected preclinical studies involving angiogenesis-associated biology.

Relevant research topics include:

  • Endothelial cell biology.
  • Angiogenesis-associated signalling.
  • Vascular cellular responses.
  • Experimental tissue models.
  • Growth factor-associated pathways.
  • Cellular migration.
  • Molecular regulatory mechanisms.

These investigations contribute to understanding vascular and tissue-associated processes.

However, angiogenesis-related activity is context-dependent and should not automatically be interpreted as beneficial.

4. Connective Tissue and Extracellular Matrix Research

Connective tissues contain cells and extracellular matrix components that provide structural support.

Preclinical research involving BPC-157 and thymosin beta-4-related peptides has intersected with experimental connective tissue biology.

Relevant research topics include:

  • Extracellular matrix regulation.
  • Collagen-associated pathways.
  • Fibroblast biology.
  • Cellular matrix interactions.
  • Experimental connective tissue models.
  • Tissue-associated signalling.
  • Molecular response profiling.

These investigations contribute to understanding connective tissue biology.

However, the available evidence does not establish that the Peps Aussie blend repairs tendons, ligaments, muscles or cartilage in humans.

5. Gastrointestinal Tissue Research

BPC-157 has been investigated in preclinical research involving gastrointestinal tissues and experimental injury models.

These studies form part of the compound’s broader research history.

Relevant research topics include:

  • Gastrointestinal epithelial biology.
  • Experimental tissue responses.
  • Cellular stress pathways.
  • Molecular signalling.
  • Animal gastrointestinal models.
  • Tissue-associated regulatory processes.
  • Comparative experimental observations.

These investigations contribute to understanding gastrointestinal tissue biology.

However, the presence of BPC-157 in a combined research blend does not establish treatment efficacy for gastrointestinal disorders.

6. Actin and Cytoskeletal Research

Actin is a structural protein involved in cellular organisation, movement and numerous regulatory processes.

Thymosin beta-4 has been investigated in relation to actin binding and cytoskeletal biology.

Relevant research topics include:

  • Actin-associated signalling.
  • Cytoskeletal organisation.
  • Cellular motility.
  • Protein–peptide interactions.
  • Experimental cell migration.
  • Structural cellular biology.
  • Molecular interaction assays.

These investigations contribute to understanding the relationship between peptides and cellular structure.

However, whether a particular TB-500 preparation shares these characteristics depends on its verified molecular identity.

7. Combination Research and Potential Peptide Interactions

Combination research examines how multiple compounds behave when studied together.

For a BPC-157 + TB-500 blend, experimental interpretation requires consideration of both components and their relative quantities.

Relevant research topics include:

  • Individual versus combined responses.
  • Component concentration ratios.
  • Potential pharmacological interactions.
  • Experimental assay design.
  • Peptide compatibility.
  • Analytical interference.
  • Comparative cellular measurements.

These investigations may contribute to understanding how distinct peptides behave in combination.

However, combination-specific synergy has not been established for the Peps Aussie research material.

Demonstrating synergy requires direct experiments comparing the individual components with the combined preparation under appropriate conditions.

8. BPC-157 + TB-500 Analytical Characterisation and Quality Research

Analytical characterisation is particularly important for research blends containing multiple peptides.

Laboratories evaluating BPC-157 + TB-500 may investigate:

  • Confirmation of BPC-157 identity.
  • Verification of the BPC-157 amino acid sequence.
  • Identification of the specific TB-500 molecular form.
  • Molecular mass determination for both components.
  • Quantitative content of each peptide.
  • Relative component proportions.
  • Chromatographic separation.
  • Related peptide impurities.
  • Stability and degradation characteristics.
  • Batch-to-batch analytical consistency.

Analytical techniques may include high-performance liquid chromatography (HPLC), mass spectrometry (MS) and other suitable methods.

A general purity result does not automatically establish the identity, content or purity of each individual peptide.

Similarly, the combined 20mg label does not establish a 10mg + 10mg composition.

BPC-157 + TB-500 20mg Research Blend Specifications

Peps Aussie lists BPC-157 + TB-500 in a nominal 20mg total size.

Specification Details
Product name BPC-157 + TB-500
Listed total size 20mg
Material type Experimental two-peptide blend
Component 1 BPC-157
Component 2 TB-500
BPC-157 commonly reported length 15 amino acid residues
BPC-157 commonly reported sequence GEPPPGKPADDAGLV
TB-500 molecular identity Requires verification
Individual component quantities Require verification
Blend ratio Not specified; requires verification
Research category Experimental tissue and cellular biology
Research areas Cellular migration, angiogenesis-associated pathways and tissue responses
Supplier Peps Aussie Australia
Intended use Laboratory research and analytical investigation only

Important: The 20mg designation refers to the total labelled blend strength. It does not establish that the preparation contains 10mg BPC-157 and 10mg TB-500.

The exact molecular identity, amino acid sequence, terminal modifications, salt form, formulation, physical appearance, fill quantity and excipients of each component should be confirmed against the applicable product label and supporting lot documentation.

The name TB-500 does not independently establish whether the supplied component corresponds to full-length thymosin beta-4 or another thymosin beta-4-derived sequence.

BPC-157 + TB-500 Certificate of Analysis (COA) and Quality Documentation

Analytical verification is particularly important when evaluating multi-component peptide research materials.

Peps Aussie maintains a dedicated resource where researchers can review available Certificates of Analysis and supporting analytical records.

View Peps Aussie Certificates of Analysis

When evaluating BPC-157 + TB-500 analytical documentation, researchers should consider:

  • Component identity: Whether both declared peptides have been identified.
  • BPC-157 sequence: Whether testing supports the expected BPC-157 identity.
  • TB-500 identity: Whether the precise TB-500 molecular form has been established.
  • Individual content: Whether the quantity of each peptide has been determined.
  • Blend ratio: Whether the relative proportions are supported by quantitative testing.
  • Purity assessment: Whether suitable methods distinguish the components and their impurities.
  • Total content: Whether testing supports the declared 20mg combined quantity.
  • Batch traceability: Whether the certificate corresponds to the supplied production lot.
  • Testing methodology: Whether the analytical techniques are appropriate for a multi-component peptide preparation.
  • Additional testing: Whether relevant contamination or other quality assessments were performed.

High-performance liquid chromatography and mass spectrometry may support peptide characterisation.

However, a general certificate does not automatically establish the individual purity, identity or quantitative content of both components.

A certificate should be interpreted according to the tests actually performed.

The availability of a certificate does not automatically establish sterility, endotoxin status, a particular purity percentage, pharmaceutical-grade manufacturing or independent verification of every production batch.

BPC-157 + TB-500 Storage and Laboratory Handling

Multi-component peptide research materials require appropriate handling to support sample integrity and experimental reproducibility.

Storage requirements depend on the exact molecular structures, formulation, packaging and validated manufacturer stability information.

Laboratories should consider:

  • Appropriate storage temperature.
  • Protection from light and moisture where necessary.
  • Suitable laboratory containers.
  • Compatibility with analytical solvents.
  • Potential interactions between the two components.
  • Stability following sample preparation.
  • Potential degradation during storage.
  • Appropriate laboratory handling and disposal procedures.

No universal storage temperature or reconstitution procedure is recommended without verified product-specific documentation.

Storage information for the individual peptides should not automatically be applied to a combined preparation.

All laboratory work should be performed by appropriately qualified personnel using validated procedures and suitable safety controls.

BPC-157 + TB-500 20mg Australia – Product Availability and Shipping

Peps Aussie maintains an Australian-based catalogue of research peptides and laboratory materials for scientific and analytical applications.

BPC-157 + TB-500 20mg is the currently listed nominal product size.

The 20mg designation refers to the combined labelled quantity, not a verified individual component split.

Pricing and ordering availability should be confirmed through the product selection area. Inventory is currently pending confirmation.

For current information regarding Australian dispatch, delivery arrangements, processing times and applicable restrictions, visit the Peps Aussie Shipping Policy.

Frequently Asked Questions About BPC-157 + TB-500

What is BPC-157 + TB-500?

BPC-157 + TB-500 is an experimental two-component peptide blend combining BPC-157 with material commercially designated TB-500.

What is BPC-157 + TB-500 studied for?

The individual components have been investigated or discussed in preclinical research involving tissue-associated responses, cellular migration, angiogenesis and molecular signalling.

What does 20mg mean for this blend?

The 20mg designation refers to the total labelled quantity of the combined product. It does not specify the amount of either individual peptide.

Does the blend contain 10mg BPC-157 and 10mg TB-500?

That cannot be assumed. The quantity of each component must be verified against the applicable product label and lot-specific analytical documentation.

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide investigated in preclinical tissue-associated and gastrointestinal research models.

What is TB-500?

TB-500 is a commercial designation associated with thymosin beta-4-derived peptide material. Its exact molecular identity requires verification.

Is TB-500 the same as thymosin beta-4?

Not necessarily. Commercial TB-500 preparations may differ in molecular identity, and published findings involving full-length thymosin beta-4 should not automatically be applied to every TB-500-labelled material.

Is the BPC-157 + TB-500 blend studied for tissue repair?

The individual components have been investigated in preclinical tissue-response models. However, this does not establish that the combined preparation repairs tissue in humans.

Does BPC-157 + TB-500 accelerate injury recovery?

There is insufficient clinical evidence to establish that this blend safely or effectively accelerates injury recovery in humans.

Does combining BPC-157 and TB-500 create a synergistic effect?

Synergy has not been established for the Peps Aussie research material. Demonstrating synergy requires direct combination-specific experimental evidence.

Is BPC-157 + TB-500 approved for human use?

No medical approval or clinical suitability is claimed for the Peps Aussie research blend.

What size does Peps Aussie list?

Peps Aussie lists BPC-157 + TB-500 in a 20mg nominal total size.

Does the blend have a Certificate of Analysis?

Available analytical documentation can be reviewed through the Peps Aussie Certificates of Analysis page. Researchers should verify the lot number and whether testing identifies and quantifies both components.

How should BPC-157 + TB-500 be stored?

Storage requirements depend on the exact molecular forms, formulation and validated stability characteristics of the combined material. Follow the manufacturer’s product-specific documentation and established laboratory procedures.

Is BPC-157 + TB-500 approved for veterinary use?

No veterinary approval or clinical suitability is claimed for the Peps Aussie research product.

It is not supplied for animal consumption, administration, diagnosis, prevention or treatment.

BPC-157 + TB-500 Research Blends at Peps Aussie Australia

Peps Aussie maintains a catalogue of laboratory research peptides and scientific materials for researchers investigating molecular biology, peptide chemistry and tissue-associated signalling.

BPC-157 + TB-500 is relevant to scientific discussions involving experimental tissue biology, cellular migration, angiogenesis-associated pathways and peptide interactions.

Researchers evaluating the 20mg blend should prioritise accurate identification of both components, verification of their individual quantities, appropriate analytical documentation, batch traceability and validated laboratory procedures.

Explore the Peps Aussie research catalogue at pepsaussie.com.


Research Use Only Disclaimer

BPC-157 + TB-500 20mg is intended strictly for laboratory research and analytical purposes only.

This product is not intended for human or animal consumption, injection, administration, injury treatment, tissue repair, sports recovery, bodybuilding, performance enhancement or therapeutic use.

Descriptions of published scientific research are provided for educational and informational purposes only. They do not establish accelerated healing, tendon or ligament repair, muscle recovery, cartilage regeneration, pain relief, clinical safety or therapeutic suitability for the material offered.

Research findings involving the individual peptides, full-length thymosin beta-4 or other related compounds should not be assumed to apply to this combined preparation without verified molecular identity, component quantities and direct supporting evidence.

No dosing, self-administration or therapeutic guidance is provided.

Additional information

Size

20mg

Reviews

There are no reviews yet.

Reviews here are by invitation. We email a link once your order has arrived, so every review comes from someone who received the product. Lost the email? Find your review link.

Related Products

Search Products